Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Sofosbuvir and Ribavirin in Adults With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with evidence of chronic HCV (all genotypes) documented pretransplantation~* HCV RNA ≥ 10,000 IU/mL at screening~* Absence of organ rejection as documented by post transplant liver biopsy taken no more than 12 months prior to baseline/Day 1 visit~* Liver transplant ≥ 6 months and ≤ 12 years prior to screening~* Naive to all nucleotide/nucleoside treatments for chronic HCV infection~Exclusion Criteria:~* Multiorgan transplant that includes heart or lung recipient~* Subjects with de novo or recurrent Hepatocellular Carcinoma(HCC) post transplant~* Current use of corticosteroids at any dose \> 5mg of prednisone/day (or equivalent dose of corticosteroid)~* Infection with hepatitis B virus (HBV) or HIV at screening~* Current, uncontrolled ascites, variceal hemorrhage, hepatic encephalopathy, hepatorenal syndrome, hepatopulmonary syndrome, or other signs of decompensated cirrhosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF+RBV (Type: EXPERIMENTAL): Participants will receive sofosbuvir+RBV for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).